Drug Profile
PGN 503
Alternative Names: PGN503Latest Information Update: 15 Sep 2022
Price :
$50
*
At a glance
- Originator Periphagen Holdings
- Class
- Mechanism of Action Nerve growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Peripheral nervous system diseases
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases(Chemotherapy-induced) in USA
- 09 Jan 2020 Candel Therapeutics acquires all oncolytic and other Herpes Simplex Virus (HSV) based assets from PeriphaGen
- 05 Jul 2016 PGN 503 is available for licensing as of 05 Jul 2016. http://www.periphagen.com/